Curious that ACHN plans to run a five-day monotherapy study for its first test of ACHN-1095 in HCV patients. (Source: today’s ACHN Canaccord webcast.)
On IDIX’s recent CC, JP Sommadossi said the new FDA mandate for HCV drugs is to start with a three-day monotherapy study following a single-dose study in healthy volunteers.
Comments?
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”